{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:01:26Z","timestamp":1790222486875,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.011","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:27:46Z","timestamp":1790220466000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperpersonalization of cancer care: From tumor location to molecular profile\u00a0\u2013\u00a0Key insights and the role of Hospital Oncology Pharmacists. A French Society for Oncology Pharmacy paper"],"prefix":"10.1016","author":[{"given":"Florence","family":"Ranchon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gine","family":"Chevrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Pourroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Cazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.07.011_bib0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-024-00216-3","article-title":"Forget lung, breast or prostate cancer: why tumour naming needs to change","volume":"626","author":"Andr\u00e9","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0325","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: Evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0330","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0335","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.pharma.2025.07.005","article-title":"Oncology Pharmacy Practice: key insights, challenges, and perspectives \u2013 a position paper from the French Society for Oncology Pharmacy (SFPO)","volume":"83","author":"Ranchon","year":"2025","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0340","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0345","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0350","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/cas.16160","article-title":"Microsatellite instability: a 2024 update","volume":"115","author":"Yamamoto","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0355","series-title":"FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0360","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0365","series-title":"FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0370","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0375","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0380","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0385","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0390","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0395","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0400","unstructured":"Sava J. FDA awards full approval to larotrectinib in NTRK+ Solid Tumors | Targeted oncology\u00a0\u2013\u00a0immunotherapy, biomarkers, and cancer pathways 2025. https:\/\/www.targetedonc.com\/view\/fda-awards-full-approval-to-larotrectinib-in-ntrk-solid-tumors (accessed November 25, 2025)."},{"key":"10.1016\/j.bulcan.2026.07.011_bib0405","series-title":"FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0415","series-title":"Burst edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0420","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0425","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0430","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0435","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0440","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0445","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/OTT.S120440","article-title":"BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study","volume":"10","author":"Cohn","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0450","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0455","series-title":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0460","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0470","series-title":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors","year":"2024"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0475","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0480","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0485","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0490","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0495","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0500","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0505","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0510","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0515","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2967\/jnumed.123.266309","article-title":"Preclinical characterization of DPI-4452: A 68Ga\/177Lu theranostic ligand for carbonic anhydrase IX","volume":"65","author":"Massi\u00e8re","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0520","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bulcan.2024.08.008","article-title":"La m\u00e9decine de pr\u00e9cision en canc\u00e9rologie\u00a0: une r\u00e9alit\u00e9\u2026 sans \u00e9quit\u00e9","volume":"112","author":"P\u00e9nault-Llorca","year":"2025","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0525","doi-asserted-by":"crossref","first-page":"101183","DOI":"10.1016\/j.lanepe.2024.101183","article-title":"PFMG2025-integrating genomic medicine into the national healthcare system in France","volume":"50","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0530","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10555-025-10274-2","article-title":"Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates","volume":"44","author":"Kim","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0535","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0540","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0545","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/1078-0432.CCR-23-0983","article-title":"Tumor-specific activity of precision medicines in the NCI-MATCH trial","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bulcan.2019.01.007","article-title":"La m\u00e9decine de pr\u00e9cision en oncologie\u00a0: challenges, enjeux et nouveaux paradigmes","volume":"106","author":"Cox","year":"2019","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0555","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bulcan.2023.07.007","article-title":"Jumeaux num\u00e9riques\u00a0: futur de la m\u00e9decine personnalis\u00e9e en canc\u00e9rologie","volume":"110","author":"Heudel","year":"2023","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0560","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0565","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.therap.2022.12.003","article-title":"Platform trials","volume":"78","author":"Roustit","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0570","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0575","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharma.2025.10.001","article-title":"The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care","volume":"84","author":"Ranchon","year":"2026","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0580","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/OP.22.00281","article-title":"Impact of medication reconciliation in oncology early phase studies: a drug-drug interaction retrospective study","volume":"20","author":"Malifarge","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0585","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5644\/ama2006-124.246","article-title":"Precision medicine in oncology pharmacy practice","volume":"48","author":"Saadeh","year":"2019","journal-title":"Acta Med Acad"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0590","doi-asserted-by":"crossref","first-page":"101524","DOI":"10.1016\/j.lanepe.2025.101524","article-title":"Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis","volume":"60","author":"Dupain","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0595","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cptl.2021.07.017","article-title":"An interprofessional education experience to promote the role of the pharmacist in precision medicine","volume":"13","author":"Calinski","year":"2021","journal-title":"Curr Pharm Teach Learn"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0600","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jval.2023.07.004","article-title":"Toward best practices for economic evaluations of tumor-agnostic therapies: a review of current barriers and solutions","volume":"26","author":"Weymann","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25760","article-title":"Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework","volume":"25","author":"Murphy","year":"2021","journal-title":"Health Technol Assess Winch Engl"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0610","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/S1470-2045(21)00337-5","article-title":"Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment","volume":"22","author":"Lenglin\u00e9","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0615","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14737167.2025.2532023","article-title":"Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies","volume":"25","author":"Zelei","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0620","unstructured":"European Society of Clinical Pharmacy. European Society of Clinical Pharmacy Website. ESCP Definition of Clinical Pharmacy n.d. https:\/\/escpweb.org\/about-us\/vision-mission-values\/."},{"key":"10.1016\/j.bulcan.2026.07.011_bib0625","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"D\u00fcrr","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.011_bib0630","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12913-020-4963-7","article-title":"Clinical, economic and organizational impact of pharmacist interventions on injectable antineoplastic prescriptions: a prospective observational study","volume":"20","author":"Zecchini","year":"2020","journal-title":"BMC Health Serv Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:27:58Z","timestamp":1790220478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0007455126003851"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperpersonalization of cancer care: From tumor location to molecular profile\u00a0\u2013\u00a0Key insights and the role of Hospital Oncology Pharmacists. A French Society for Oncology Pharmacy paper","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}